Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 19Phase 1 17Phase 3 6Phase NA 2

Status

Active not recruiting 3Completed 2Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 1129Carcinoma, Non-Small-Cell Lung 718Neoplasms 546Prostatic Neoplasms 505Colorectal Neoplasms 439Multiple Myeloma 338Lung Neoplasms 310Neoplasm Metastasis 289Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 246Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 172Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 162Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

Ipilimumab 3tremelimumab 1tilsotolimod 1spartalizumab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Diabetes Mellitus, Insulin-Dependent, 12 × Clear all
NCT07000149 2026-03-10

eVOLVE-RCC02

AstraZeneca

Phase 3 Active not recruiting
1,116 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05751928 2025-07-08

NEO-MIMAJOR

Biocad

Phase 3 Active not recruiting
411 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT05732805 2025-02-27

OCTAVA

Biocad

Phase 3 Active not recruiting
270 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03302234 2023-09-26

KEYNOTE-598

Merck Sharp & Dohme LLC

Phase 3 Completed
568 enrolled 20 charts
Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03084471 2022-12-22

STRONG

AstraZeneca

Phase 3 Completed
867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡